High-Risk Human Papillomavirus Infection in Latvian Male Kidney Transplant Recipients / Augsta Riska Cilvēka Papilomas Vīrusa Infekcija Vīriešu Dzimuma Nieru Transplantāta Saņēmējiem Latvijā

Open access


Kidney transplant recipients have higher incidence of human papillomavirus (HPV)-related malignancies, but studies on the natural history of HPV infection are insufficient, especially regarding in male recipients. The aim of this study was to evaluate the course of high-risk HPV (HR-HPV) infection after kidney allograft transplantation in male recipients: to estimate frequency and activity of HR-HPV infection under immune system suppression. Twenty male renal recipients (age 20 - 68) were enrolled in this investigation and examined in dynamics. Peripheral EDTA-blood samples and urine samples were collected from each patient 2 weeks, 6 months and 12 months after transplantation. Polymerase chain reaction (PCR) with consensus primers was used for initial detection of high range HPV types, a commercial qPCR kit for detection of HR-HPV load in urine samples and ELISA for detection of serum IgG class antibodies to HR-HPV L1-capsid protein. Overall, combining molecular (HR-HPV genomic sequences detected by real-time PCR) and serological studies (IgG class antibodies to HR-HPV L1-capsids’ protein), high frequency of HRHPV infection among male kidney transplant recipients (9/20; 45%) was showed. However, the majority of HR-HPV positive recipients (7/9; 78%) showed signs of infection clearance. It means that, despite the applied immune suppressive therapy, the host’s immune system is capable of dealing with HR-HPV infection up to the 12th month after transplantation. However, the sample size should be increased to enable through statistical analysis before final conclusions are made.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • Adami J. Gäbel H. Lindelöf B. Ekström K. Rydh B. Glimelius B. Ekbom A. Adami H. O. Granath F. (2003). Cancer risk following organ transplantation: A nationwide cohort study in Sweden. Brit. J. Cancer. 89 (7) 1221-1227.

  • Afonso L.A. Cordeiro T. I. Carestiato F. N. Ornellas A. A. Alves G. Cavalcanti S. M. (2016). High-risk human papillomavirus infection of the foreskin in asymptomatic Mmen and patients with phimosis. J. Urol. Jan. 18 pii: S0022-5347 (16)00040-9.

  • Albero G. Castellsagué X. Lin H. Y. Fulp W. Villa L. L. Lazcano- Ponce E. Papenfuss M. Abrahamsen M. Salmerón J. Quiterio M. Nyitray A. G. Lu B. Bosch F. X. Giuliano A. R. (2014). Male circumcision and the incidence and clearance of genital human papillomavirus (HPV) infection in men: The HPV infection in men (HIM) cohort study. BMC Infect. Dis. 14 75.

  • Amirian E. S. Adler-Storthz K. Scheurer M. E. (2013). Associations between human herpesvirus-6 human papillomavirus and cervical cancer. Cancer Lett. 336 (1) 18-23.

  • Brendle S. A. Bywaters S. M. Christensen N. D. (2014). Pathogenesis of infection by human papillomavirus. Curr. Probl. Dermatol. 45 47-57.

  • Buell J. F. Gross T. G. Woodle E. S. Malignancy after transplantation. (2005). Transplantation 80 (2 Suppl) S254-64.

  • Burd E. M. Human papillomavirus and cervical cancer. (2003). Clin. Microbiol. Rev. 16 (1) 1-17.

  • Cai T. Perletti G. Meacci F. Magri V. Verze P. Palmieri A. Mazzoli S. Santi R. Nesi G. Mirone V. Bartoletti R. (2016). Natural history of human papillomavirus infection in non-vaccinated young males: Low clearance probability inhigh-risk genotypes. Eur. J. Clin. Microbiol. Infect. Dis. 35 (3) 463-469.

  • Coscia M. F. Monno R. Ballini A. Mirgaldi R. Dipalma G. Pettini F. Cristallo V. Inchingolo F. Foti C. de Vito D. (2015) Human papilloma virus (HPV) genotypes prevalence in a region of South Italy (Apulia). Ann. Ist. Super. Sanita 51 (3) 248-251.

  • Forman D. de Martel C. Lacey C. J. Soerjomataram I. Lortet-Tieulent J. Bruni L. Vignat J. Ferlay J. Bray F. Plummer M. Franceschi S. (2012). Global burden of human papillomavirus and related diseases. Vaccine 30 (Suppl 5) F12-23.

  • Frazer I. H. (2009). Interaction of human papillomaviruses with the host immune system: A well evolved relationship. Virology 384 (2) 410-414.

  • Genzer O. El-Sayegh S. E. Kleiner M. J. Castellanos M. R. (2012). Male human papillomavirus infection post-kidney transplant: An overlooked disease. Transplant Res. 1 (1) 21.

  • Golijow C. D. Pérez L. O. Smith J. S. Abba M. C. (2005). Human papillomavirus DNA detection and typing in male urine samples from a high-risk population from Argentina. J. Virol. Methods 124 (1-2) 217-220.

  • Grulich A. E. van Leeuwen M. T. Falster M. O. Vajdic C. M. (2007). Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: A meta-analysis. Lancet 370 (9581) 59-67.

  • Halpert R. Fruchter R. G. Sedlis A. Butt K. Boyce J. G. Sillman F. H. (1986). Human papillomavirus and lower genital neoplasia in renal transplant patients. Obstet. Gynecol. 68 (2) 251-258.

  • Jacobs M. V. de Roda Husman A. M. van den Brule A. J. Snijders P. J. Meijer C. J. Walboomers J. M. (1995). Group-specific differentiation between high- and low-risk human papillomavirus genotypes by general primer-mediated PCR and two cocktails of oligonucleotide probes. J. Clin. Microbiol. 33 (4) 901-905.

  • Leiros G. J. Galliano S. R. Sember M. E. Kahn T. Schwarz E. Eiguchi K. (2005). Detection of human papillomavirus DNA and p53 codon 72 polymorphism in prostate carcinomas of patients from Argentina. BMC Urol. 5 15.

  • Li X. Li M. Yang Y. Zhong X. Feng B. Xin H. Li Z. Jin Q. Gao L. (2016). Anal HPV/HIV co-infection among men who have sex with men: A cross-sectional survey from three cities in China. Sci. Rep. 6 21368.

  • Meeuwis K. A. Hilbrands L. B. IntHout J. Slangen B. F. Hendriks I. M. Hinten F. Christiaans M. H. Quint W. G. van de Kerkhof P. C. Massuger L. F. Hoitsma A. J. van Rossum M. M. Melchers W. J. de Hullu J. A. (2015). Cervicovaginal HPV infection in female renal transplant recipients: An observational self-sampling based cohort study. Amer. J. Transplant. 15 (3) 723-733.

  • Muñoz N. Bosch F. X. de Sanjosé S. Herrero R. Castellsagué X. Shah K. V. Snijders P. J. Meijer C. J. International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. (2003). Epidemiologic classification of human papillomavirus types associated with cervical cancer. New Engl. J. Med. 348 (6) 518-527.

  • Nyitray A. G. Carvalho da Silva R. J. Baggio M. L. Smith D. Abrahamsen M. Papenfuss M. Lin H. Y. Quiterio M. Salmerón J. Lazcano-Ponce E. Villa L. L. Giuliano A. R. (2011). Six-month incidence persistence and factors associated with persistence of anal human papillomavirus in men: The HPV in men study. J. Infect. Dis. 204 (11) 1711-1722.

  • Parkin D. M. (2006). The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer. 118 (12) 3030-3044.

  • Pathak N. Dodds J. Zamora J. Khan K. (2014). Accuracy of urinary human papillomavirus testing for presence of cervical HPV: Systematic review and meta-analysis. Brit. Med. J. 349 g5264.

  • Scott M. Nakagawa M. Moscicki A. B. (2001). Cell-mediated immune response to human papillomavirus infection. Clin. Diagn. Lab. Immunol. 8 (2) 209-220.

  • Shukla S. Bharti A. C. Mahata S. Hussain S. Kumar R. Hedau S. Das B. C. (2009). Infection of human papillomaviruses in cancers of different human organ sites. Indian J. Med. Res. 130 (3) 222-233.

  • Skiba D. Mehlhorn G. Fasching P. A. Beckmann M. W. Ackermann S. (2006). Prognostic significance of serum antibodies to HPV-16 L1 virus- like particles in patients with invasive cervical cancer. Anticancer Res. 26(6C) 4921-4926.

  • Stanley M. (2008). Immunobiology of HPV and HPV vaccines. Gynecol. Oncol. 109 (2 Suppl) S15-21.

  • Stanley M. A. Sterling J. C. (2014). Host responses to infection with human papillomavirus. Curr. Probl. Dermatol. 45 58-74.

  • Tillou X. Doerfler A. (2014). Urological tumors in renal transplantation. Minerva Urol. Nefrol. 66 (1) 57-67.

  • Vandamme A. M. Fransen K. Debaisieux L. Marissens D. Sprecher S. Vaira D. Vandenbroucke A. T. Verhofstede C. (1995). Standardisation of primers and an algorithm for HIV-1 diagnostic PCR evaluated in patients harbouring strains of diverse geographical origin. The Belgian AIDS Reference Laboratories. J. Virol. Methods 51 (2-3) 305-316.

Journal information
Impact Factor

CiteScore 2018: 0.3

SCImago Journal Rank (SJR) 2018: 0.137
Source Normalized Impact per Paper (SNIP) 2018: 0.192

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 272 132 2
PDF Downloads 126 84 1